Associate Professor, Department of BiochemistryTumor Cell Biology ProgramPhD, Immunology, 1995, Hebrew University, JerusalemPostdoc, 1995-2000, Massachusetts General Hospital, Boston MA
Contact information2500 N State St., Room G759Jackson, MS 39216Phone: (601) 815-6765Fax: (601) 815-6806E-mail: email@example.com
The broad goal of our research is to understand signaling processes and networking downstream of growth factor receptors at molecular and mechanistic levels and to apply this knowledge to address cancer and lifespan related problems. Intracellular signaling pathways are required for the regulation of many physiological processes under normal conditions, however, when deregulated, can result in various pathological conditions, primarily cancer. For instance, increased activation of growth factor receptors and mutations in downstream signaling molecules such as Ras, Raf and PI3K are associated with more than half of all human cancers. The study of signaling pathways allowed the recent development of targeted therapies such as Gleevec, targeting abl, Herceptin, targeting Her2 and Sorafenib, targeting Raf and the VEGF receptor. Specifically, our program involves defining functional and regulatory aspects of four distinct pathways in cancer and lifespan control through employing molecular and biochemical methodologies combined with transgenic mice models. These pathways include the Ras-Raf-MAPK pathway, the PI3K-AKT-FoxO pathway, 14-3-3-regulated pathways and the nicotinamide-sirtuin pathway. It is broadly accepted today that understanding the complex nature of intracellular signaling pathways and their intricate signaling networks will have significant clinical benefits by identifying new candidates for therapeutic intervention and by devising combination therapies. The Ras-Raf-MAPK and the PI3K-AKT-FoxO pathways are good examples, showing positive and negative feedback regulations within the cascade as well as cross-talk relations with each other. The significance of the integration of signals through these pathways is emphasized by the apparent need to inhibit both pathways for effective cancer growth attention.
2008 Session Chair, Gordon Research Conference on Biology of 14-3-3 Proteins, Ventura, CA, February 24-29.
2500 North State Street
Jackson, MS 39216